Arpida Comments On FDA's Anti-infective Drugs Advisory Committee Outcome Arpida (SWX: ARPN) announced that the Anti-infective
Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous iclaprim, an antibiotic currently in development for the treatment of patients with complicated skin and skin structure infections (cSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Source: www.medicalnewstoday.comCHMP Recommends Approval Of New Indication For Enbrel(R) As Treatment For Severe Psoriasis In Paediatric Patients The European Committee for Medicinal Products for Human Use (CHMP) announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque psoriasis. If approved by the European Commission, following the Committee's recommendation, Enbrel will become the first biologic treatment indicated for severe psoriasis in children and adolescents.
Source: www.medicalnewstoday.comPregnant Women Who Do Aquarobics Have Easier Deliveries A course of organised water aerobics has been shown to reduce the amount of pain-killing medication women request during labor. Research published in BioMed Central's open access journal Reproductive
Health has shown that, as well as being safe, the gentle exercise has the benefit of making it easier to give birth.
Source: www.medicalnewstoday.comFDA Approves Tapentadol Immediate-Release Tablets For Relief Of Moderate To Severe Acute Pain Millions of Americans with moderate to severe acute pain and their
health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the U.S. Food and Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults 18 years of age or older. Tapentadol is a new centrally acting oral analgesic.
Source: www.medicalnewstoday.comSystems Biology Brings Hope Of Speeding Up Drug Development Almost every day brings news of an apparent breakthrough against cancer, infectious diseases, or metabolic conditions like diabetes, but these rarely translate into effective therapies or
drugs, and even if they do clinical development usually takes well over a decade.
Source: www.medicalnewstoday.comResearchers At Leeds, UK Reshape The Future Of Drug Discovery Scientists in Leeds have devised a new way to create the next generation of man-made molecules in a breakthrough that could revolutionise drug development. Creating new
drugs to combat disease and illness requires the completion of a complex 3D jigsaw. The shape of the drug must be right to allow it to bind to a specific disease-related protein and to work effectively, and this shape is determined by the core framework of the molecule.
Source: www.medicalnewstoday.comFDA Approves Promacta(R) (Eltrombopag), The First Oral Medication To Increase Platelet Production For People With Serious Blood Disorder GlaxoSmithKline (NYSE: GSK) announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Source: www.medicalnewstoday.comRoActemra Receives Positive Opinion In Europe For The Treatment Of Rheumatoid Arthritis Roche announced that the European Committee on Human Medicinal Products (CHMP) has given a positive recommendation for RoActemra (tocilizumab, known as Actemra outside of the EU), in combination with methotrexate (MTX), for the treatment of adult patients with moderate to severe rheumatoid arthri
Source: www.medicalnewstoday.com
# posted by Network @ 2:00 PM
